|
Index | - | P/E | - | EPS (ttm) | -0.51 | Insider Own | 46.08% | Shs Outstand | 25.05M | Perf Week | -15.10% |
Market Cap | 59.45M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 16.34M | Perf Month | -21.80% |
Income | -12.80M | PEG | - | EPS next Q | - | Inst Own | 1.50% | Short Float | 0.47% | Perf Quarter | -17.13% |
Sales | 0.40M | P/S | 148.62 | EPS this Y | -3.20% | Inst Trans | - | Short Ratio | 1.23 | Perf Half Y | -39.18% |
Book/sh | 0.35 | P/B | 5.94 | EPS next Y | - | ROA | -112.80% | Target Price | 9.50 | Perf Year | -62.18% |
Cash/sh | 0.21 | P/C | 10.08 | EPS next 5Y | - | ROE | -239.40% | 52W Range | 1.95 - 11.69 | Perf YTD | -38.64% |
Dividend | - | P/FCF | - | EPS past 5Y | -8.30% | ROI | -120.50% | 52W High | -82.21% | Beta | 0.57 |
Dividend % | - | Quick Ratio | 2.60 | Sales past 5Y | - | Gross Margin | 98.60% | 52W Low | 6.67% | ATR | 0.19 |
Employees | 28 | Current Ratio | 2.60 | Sales Q/Q | 300.00% | Oper. Margin | - | RSI (14) | 38.50 | Volatility | 9.76% 7.94% |
Optionable | No | Debt/Eq | 0.18 | EPS Q/Q | -115.60% | Profit Margin | - | Rel Volume | 0.21 | Prev Close | 2.09 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 63.03K | Price | 2.08 |
Recom | - | SMA20 | -12.52% | SMA50 | -15.52% | SMA200 | -26.27% | Volume | 13,402 | Change | -0.48% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite